预防医学

订阅

MedSci主页 / 所有栏目 / 预防医学

Clinica Chimica Acta：血清nardilysin水平在预测成人恶性脑梗死患者30天死亡率中的临床意义

2019-09-13 gladiator MedSci原创

血清nardilysin脑梗
关注

<span lang="EN-US" style="font-size:12.0pt;mso-bidi-font-size: 14.0pt;font-family:&quot;Calibri&quot;,&quot;sans-serif&quot;;mso-fareast-font-family:宋体; mso-bidi-font-family:&quot;Times New Roman&qu

Nardilysin是一种金属内肽酶，在多种炎症性疾病中发挥重要作用。恶性脑梗死(Glasgow coma scale score <9)与高死亡率风险相关。在此，本研究拟探讨血清纳地平水平与恶性脑梗死患者预后的关系。

在研究开始时，研究人员对105例恶性脑梗死患者和105例健康对照者血清nardilysin浓度进行了定量。用多变量分析估计nardilysin浓度与30天死亡率和总生存率的关系。

研究发现，与对照组相比，患者的血清nardilysin浓度明显升高。Nardilysin浓度与格拉斯哥昏迷评分和血清c反应蛋白浓度呈显著相关。血清nardilysin可独立预测30天死亡率和总生存率。在接收者工作特性曲线下，发现其具有较高的分辨能力。

脑梗死后血清nardilysin浓度升高与脑卒中严重程度、炎症程度和较高的死亡风险密切相关，本研究证实血清nardilysin是恶性脑梗死的一种潜在的预后生物标志物。

原始出处：

Fang-Hui Chen，Yi Wang，Clinical determination of serum nardilysin levels in predicting 30-day mortality among adults with malignant cerebral infarction

本文系梅斯医学（MedSci）原创编译整理，转载需授权！


版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1977815, encodeId=652819e781589, content=<a href='/topic/show?id=93a211600a' target=_blank style='color:#2F92EE;'>#30天#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1160, encryptionId=93a211600a, topicName=30天)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Sep 17 00:38:00 CST 2019, time=2019-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849693, encodeId=d8ed1849693e8, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sun Aug 16 22:38:00 CST 2020, time=2020-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465150, encodeId=83cb14651507f, content=<a href='/topic/show?id=2dea8489010' target=_blank style='color:#2F92EE;'>#脑梗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84890, encryptionId=2dea8489010, topicName=脑梗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccf56689148, createdName=karmond, createdTime=Sun Sep 15 12:38:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471828, encodeId=9be914e1828e1, content=<a href='/topic/show?id=18431252075' target=_blank style='color:#2F92EE;'>#Nardilysin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12520, encryptionId=18431252075, topicName=Nardilysin)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a687156403, createdName=zhangbaojun, createdTime=Sun Sep 15 12:38:00 CST 2019, time=2019-09-15, status=1, ipAttribution=)]
    2019-09-17 仁者大医

    #30天#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1977815, encodeId=652819e781589, content=<a href='/topic/show?id=93a211600a' target=_blank style='color:#2F92EE;'>#30天#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1160, encryptionId=93a211600a, topicName=30天)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Sep 17 00:38:00 CST 2019, time=2019-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849693, encodeId=d8ed1849693e8, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sun Aug 16 22:38:00 CST 2020, time=2020-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465150, encodeId=83cb14651507f, content=<a href='/topic/show?id=2dea8489010' target=_blank style='color:#2F92EE;'>#脑梗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84890, encryptionId=2dea8489010, topicName=脑梗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccf56689148, createdName=karmond, createdTime=Sun Sep 15 12:38:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471828, encodeId=9be914e1828e1, content=<a href='/topic/show?id=18431252075' target=_blank style='color:#2F92EE;'>#Nardilysin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12520, encryptionId=18431252075, topicName=Nardilysin)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a687156403, createdName=zhangbaojun, createdTime=Sun Sep 15 12:38:00 CST 2019, time=2019-09-15, status=1, ipAttribution=)]
    2020-08-16 windight

    #CTA#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1977815, encodeId=652819e781589, content=<a href='/topic/show?id=93a211600a' target=_blank style='color:#2F92EE;'>#30天#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1160, encryptionId=93a211600a, topicName=30天)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Sep 17 00:38:00 CST 2019, time=2019-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849693, encodeId=d8ed1849693e8, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sun Aug 16 22:38:00 CST 2020, time=2020-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465150, encodeId=83cb14651507f, content=<a href='/topic/show?id=2dea8489010' target=_blank style='color:#2F92EE;'>#脑梗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84890, encryptionId=2dea8489010, topicName=脑梗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccf56689148, createdName=karmond, createdTime=Sun Sep 15 12:38:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471828, encodeId=9be914e1828e1, content=<a href='/topic/show?id=18431252075' target=_blank style='color:#2F92EE;'>#Nardilysin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12520, encryptionId=18431252075, topicName=Nardilysin)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a687156403, createdName=zhangbaojun, createdTime=Sun Sep 15 12:38:00 CST 2019, time=2019-09-15, status=1, ipAttribution=)]
    2019-09-15 karmond

    #脑梗#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1977815, encodeId=652819e781589, content=<a href='/topic/show?id=93a211600a' target=_blank style='color:#2F92EE;'>#30天#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1160, encryptionId=93a211600a, topicName=30天)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Sep 17 00:38:00 CST 2019, time=2019-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849693, encodeId=d8ed1849693e8, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sun Aug 16 22:38:00 CST 2020, time=2020-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465150, encodeId=83cb14651507f, content=<a href='/topic/show?id=2dea8489010' target=_blank style='color:#2F92EE;'>#脑梗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84890, encryptionId=2dea8489010, topicName=脑梗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccf56689148, createdName=karmond, createdTime=Sun Sep 15 12:38:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471828, encodeId=9be914e1828e1, content=<a href='/topic/show?id=18431252075' target=_blank style='color:#2F92EE;'>#Nardilysin#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12520, encryptionId=18431252075, topicName=Nardilysin)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a687156403, createdName=zhangbaojun, createdTime=Sun Sep 15 12:38:00 CST 2019, time=2019-09-15, status=1, ipAttribution=)]
    2019-09-15 zhangbaojun

    #Nardilysin#

    0